Nxera completes convertible bond buyback and consent solicitation

Nxera Pharma Co., Ltd. announced the successful completion of its tender offer and consent solicitation for its outstanding convertible bonds due 2028. The company received the necessary electronic consent for an extraordinary resolution to amend and waive certain provisions in connection with the trust deed, leading to the cancellation of the planned meeting. A supplemental trust deed will be executed to give effect to this resolution.

The tender offer resulted in the purchase of Euro-yen Denominated Convertible Bonds due 2028 with a total purchase price of 4,837,500,000 yen for a principal amount of 5,000,000,000 yen. This price reflects a purchase rate of 9,675,000 yen per 10,000,000 yen principal amount, excluding accrued interest. Following this buyback, the outstanding principal amount of the convertible bonds stands at 27,000,000,000 yen.

The original convertible bonds, issued on 14 December 2023, had an issue amount of 32,000,000,000 yen with a maturity date of 14 December 2028 and a coupon of 0.25% per annum. The conversion price as of 26 November 2025 was 1,782 yen.